State of Alaska Department of Revenue lessened its stake in Catalent, Inc. (NYSE:CTLT) by 4.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,761 shares of the company’s stock after selling 1,221 shares during the quarter. State of Alaska Department of Revenue’s holdings in Catalent were worth $2,785,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. HM Payson & Co. acquired a new position in shares of Catalent in the 3rd quarter valued at $25,000. Wetherby Asset Management Inc. acquired a new position in shares of Catalent in the 3rd quarter valued at $366,000. Strs Ohio boosted its holdings in shares of Catalent by 10.3% in the 3rd quarter. Strs Ohio now owns 303,307 shares of the company’s stock valued at $25,981,000 after purchasing an additional 28,447 shares during the last quarter. Sei Investments Co. raised its stake in shares of Catalent by 3.4% in the 3rd quarter. Sei Investments Co. now owns 349,617 shares of the company’s stock valued at $29,924,000 after acquiring an additional 11,471 shares during the period. Finally, Van ECK Associates Corp raised its stake in shares of Catalent by 8.9% in the 3rd quarter. Van ECK Associates Corp now owns 127,437 shares of the company’s stock valued at $10,917,000 after acquiring an additional 10,387 shares during the period. Institutional investors own 97.84% of the company’s stock.
In other news, insider Karen Flynn sold 2,478 shares of Catalent stock in a transaction dated Monday, January 11th. The shares were sold at an average price of $112.30, for a total value of $278,279.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Steven L. Fasman sold 2,425 shares of Catalent stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $100.99, for a total transaction of $244,900.75. The disclosure for this sale can be found here. Insiders sold a total of 19,163 shares of company stock valued at $1,990,667 over the last ninety days. Company insiders own 1.00% of the company’s stock.
Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 3rd. The company reported $0.43 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.06. The company had revenue of $845.70 million during the quarter, compared to the consensus estimate of $812.87 million. Catalent had a net margin of 9.25% and a return on equity of 14.20%. The company’s revenue was up 27.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.26 EPS. As a group, sell-side analysts expect that Catalent, Inc. will post 2.35 earnings per share for the current fiscal year.
A number of equities analysts have recently commented on the stock. BidaskClub raised shares of Catalent from a “hold” rating to a “buy” rating in a research note on Tuesday, December 22nd. Deutsche Bank Aktiengesellschaft raised their target price on shares of Catalent from $91.00 to $100.00 and gave the company a “hold” rating in a research note on Thursday, November 5th. Morgan Stanley raised their target price on shares of Catalent from $98.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, November 4th. Argus raised their target price on shares of Catalent from $100.00 to $110.00 in a research note on Thursday, September 24th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Catalent from $110.00 to $130.00 and gave the stock an “overweight” rating in a research note on Friday, January 8th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Catalent presently has a consensus rating of “Buy” and an average target price of $110.30.
Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.